Eric Jonasch, MD, presents the case of a 72-year-old man with advanced renal cell carcinoma, shares his initial impression.
A 72-Year-Old Male with Advanced Renal Cell Carcinoma
Dr Eric Jonasch factors that contribute to a patient’s risk status, and how a patient’s risk status impacts front-line treatment choices for patients with advanced RCC.
Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.
Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.
Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
